Merck & Co.
AWARDS
NEWS
The U.S. Food and Drug Administration has a busy week planned for drug review. Here’s a look at this week’s schedule.
It was a very busy week for clinical trial news. Here’s a look.
Screening using EMR data could help with early identification of Alzheimer’s disease risk
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) proved itself effective in yet another cancer indication.
“We appreciate Merck’s willingness to work with us on the advancement of plasma kallikrein inhibitors for DME, and we respect their decision not to move forward,” said Andrew Crockett, KalVista’s chief executive officer.
It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.
JOBS
IN THE PRESS